Search

Your search keyword '"Liu, Chen‐Hua"' showing total 707 results
Start Over Author "Liu, Chen‐Hua"
707 results on '"Liu, Chen‐Hua"'

1. Benefits of Hepatitis C Viral Eradication: A Real-World Nationwide Cohort Study in Taiwan

Author

Chang, Chin-Wei, Hsu, Wei-Fan, Tseng, Kuo-Chih, Chen, Chi-Yi, Cheng, Pin-Nan, Hung, Chao-Hung, Lo, Ching-Chu, Bair, Ming-Jong, Chen, Chien-Hung, Lee, Pei-Lun, Lin, Chun-Yen, Kuo, Hsing-Tao, Chen, Chun-Ting, Yang, Chi-Chieh, Huang, Jee-Fu, Tai, Chi-Ming, Hu, Jui-Ting, Lin, Chih-Lang, Su, Wei-Wen, Tsai, Wei-Lun, Huang, Yi-Hsiang, Cheng, Chien-Yu, Lin, Chih-Lin, Wang, Chia-Chi, Yang, Sheng-Shun, Mo, Lein-Ray, Chen, Guei-Ying, Chang, Chun-Chao, Wang, Szu-Jen, Huang, Chia-Sheng, Hsieh, Tsai-Yuan, Lin, Chih-Wen, Lee, Tzong-Hsi, Chong, Lee-Won, Huang, Chien-Wei, Chang, Shiuh-Nan, Tsai, Ming-Chang, Hsu, Shih-Jer, Kao, Jia-Horng, Liu, Chun-Jen, Liu, Chen-Hua, Lin, Han-Chieh, Tsai, Pei-Chien, Yeh, Ming-Lun, Huang, Chung-Feng, Dai, Chia-Yen, Chuang, Wan-Long, Yu, Ming-Lung, and Peng, Cheng-Yuan

Published
2024
Full Text
View/download PDF

2. Dynamic change of metabolic dysfunction-associated steatotic liver disease in patients with hepatitis C virus infection after achieving sustained virologic response with direct-acting antivirals

Author

Liu, Chen-Hua, Chang, Yu-Ping, Fang, Yu-Jen, Cheng, Pin-Nan, Chen, Chi-Yi, Kao, Wei-Yu, Lin, Chih-Lin, Yang, Sheng-Shun, Shih, Yu-Lueng, Peng, Cheng-Yuan, Tsai, Ming-Chang, Huang, Shang-Chin, Su, Tung-Hung, Tseng, Tai-Chung, Liu, Chun-Jen, Chen, Pei-Jer, and Kao, Jia-Horng

Published
2024
Full Text
View/download PDF

10. Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan

Author

Liu, Chen-Hua, Peng, Cheng-Yuan, Liu, Chun-Jen, Chen, Chi-Yi, Lo, Ching-Chu, Tseng, Kuo-Chih, Su, Pei-Yuan, Kao, Wei-Yu, Tsai, Ming-Chang, Tung, Hung-Da, Cheng, Hao-Tsai, Lee, Fu-Jen, Huang, Chia-Sheng, Huang, Ke-Jhang, Shih, Yu-Lueng, Yang, Sheng-Shun, Wu, Jo-Hsuan, Lai, Hsueh-Chou, Fang, Yu-Jen, Chen, Po-Yueh, Hwang, Jow-Jyh, Tseng, Chi-Wei, Su, Wei-Wen, Chang, Chun-Chao, Lee, Pei-Lun, Chen, Jyh-Jou, Chang, Chi-Yang, Hsieh, Tsai‐Yuan, Chang, Chung-Hsin, Huang, Yi-Jie, and Kao, Jia-Horng

Published
2023
Full Text
View/download PDF

17. Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan

Author

Tsai, Pei-Chien, Kuo, Hsing-Tao, Hung, Chao-Hung, Tseng, Kuo-Chih, Lai, Hsueh-Chou, Peng, Cheng-Yuan, Wang, Jing-Houng, Chen, Jyh-Jou, Lee, Pei-Lun, Chien, Rong-Nan, Yang, Chi-Chieh, Lo, Gin-Ho, Kao, Jia-Horng, Liu, Chun-Jen, Liu, Chen-Hua, Yan, Sheng-Lei, Bair, Ming-Jong, Lin, Chun-Yen, Su, Wei-Wen, Chu, Cheng-Hsin, Chen, Chih-Jen, Tung, Shui-Yi, Tai, Chi-Ming, Lin, Chih-Wen, Lo, Ching-Chu, Cheng, Pin-Nan, Chiu, Yen-Cheng, Wang, Chia-Chi, Cheng, Jin-Shiung, Tsai, Wei-Lun, Lin, Han-Chieh, Huang, Yi-Hsiang, Yeh, Ming-Lun, Huang, Chung-Feng, Hsieh, Meng-Hsuan, Huang, Jee-Fu, Dai, Chia-Yen, Chung, Wan-Long, Chen, Chi-Yi, and Yu, Ming-Lung

Published
2023
Full Text
View/download PDF

19. Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4–6 infection: Real-world evidence from a nationwide registry in Taiwan

Author

Lo, Ching-Chu, Huang, Chung-Feng, Cheng, Pin-Nan, Tseng, Kuo-Chih, Chen, Chi-Yi, Kuo, Hsing-Tao, Huang, Yi-Hsiang, Tai, Chi-Ming, Peng, Cheng-Yuan, Bair, Ming-Jong, Chen, Chien-Hung, Yeh, Ming-Lun, Lin, Chih-Lang, Lin, Chun-Yen, Lee, Pei-Lun, Chong, Lee-Won, Hung, Chao-Hung, Chang, Te Sheng, Huang, Jee-Fu, Yang, Chi-Chieh, Hu, Jui-Ting, Lin, Chih-Wen, Chen, Chun-Ting, Wang, Chia-Chi, Su, Wei-Wen, Hsieh, Tsai-Yuan, Lin, Chih-Lin, Tsai, Wei-Lun, Lee, Tzong-Hsi, Chen, Guei-Ying, Wang, Szu-Jen, Chang, Chun-Chao, Mo, Lein-Ray, Yang, Sheng-Shun, Wu, Wen-Chih, Huang, Chia-Sheng, Hsiung, Chou-Kwok, Kao, Chien-Neng, Tsai, Pei-Chien, Liu, Chen-Hua, Lee, Mei-Hsuan, Liu, Chun-Jen, Dai, Chia-Yen, Chuang, Wan-Long, Lin, Han-Chieh, Kao, Jia-Horng, and Yu, Ming-Lung

Published
2022
Full Text
View/download PDF

21. Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR)

Author

Huang, Chung-Feng, Tseng, Kuo-Chih, Cheng, Pin-Nan, Hung, Chao-Hung, Lo, Ching-Chu, Peng, Cheng-Yuan, Bair, Ming-Jong, Yeh, Ming-Lun, Chen, Chien-Hung, Lee, Pei-Lun, Lin, Chun-Yen, Kuo, Hsing-Tao, Chen, Chun-Ting, Yang, Chi-Chieh, Huang, Jee-Fu, Tai, Chi-Ming, Hu, Jui-Ting, Lin, Chih-Lang, Su, Wei-Wen, Tsai, Wei-Lun, Huang, Yi-Hsiang, Cheng, Chien-Yu, Lin, Chih-Lin, Wang, Chia-Chi, Yang, Sheng-Shun, Mo, Lein-Ray, Chen, Guei-Ying, Chang, Chun-Chao, Wang, Szu-Jen, Huang, Chia-Sheng, Hsieh, Tsai-Yuan, Lin, Chih-Wen, Lee, Tzong-Hsi, Chong, Lee-Won, Huang, Chien-Wei, Chang, Shiuh-Nan, Tsai, Ming-Chang, Hsu, Shih-Jer, Kao, Jia-Horng, Liu, Chun-Jen, Liu, Chen-Hua, Lin, Han-Chieh, Lee, Mei-Hsuan, Tsai, Pei-Chien, Dai, Chia-Yen, Chuang, Wan-Long, Chen, Chi-Yi, and Yu, Ming-Lung

Published
2022
Full Text
View/download PDF

23. Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan

Author

Cheng, Pin-Nan, Mo, Lein-Ray, Chen, Chun-Ting, Chen, Chi-Yi, Huang, Chung-Feng, Kuo, Hsing-Tao, Lo, Ching-Chu, Tseng, Kuo-Chih, Huang, Yi-Hsiang, Tai, Chi-Ming, Peng, Cheng-Yuan, Bair, Ming-Jong, Chen, Chien-Hung, Yeh, Ming-Lun, Lin, Chih-Lang, Lin, Chun-Yen, Lee, Pei-Lun, Chong, Lee-Won, Hung, Chao-Hung, Chang, Te Sheng, Huang, Jee-Fu, Yang, Chi-Chieh, Hu, Jui-Ting, Lin, Chih-Wen, Wang, Chia-Chi, Su, Wei-Wen, Hsieh, Tsai-Yuan, Lin, Chih-Lin, Tsai, Wei-Lun, Lee, Tzong-Hsi, Chen, Guei-Ying, Wang, Szu-Jen, Chang, Chun-Chao, Yang, Sheng-Shun, Wu, Wen-Chih, Huang, Chia-Sheng, Chou, Kwok-Hsiung, Kao, Chien-Neng, Tsai, Pei-Chien, Liu, Chen-Hua, Lee, Mei-Hsuan, Cheng, Chien-Yu, Tsai, Ming-Chang, Liu, Chun-Jen, Dai, Chia-Yen, Lin, Han-Chieh, Kao, Jia-Horng, Chuang, Wan-Long, and Yu, Ming-Lung

Published
2022
Full Text
View/download PDF

24. Four weeks of off‐treatment follow‐up is sufficient to determine virologic responses at off‐treatment week 12 in patients with hepatitis C virus infection receiving fixed‐dose pangenotypic direct‐acting antivirals

Author

Liu, Chen‐Hua, primary, Chang, Yu‐Ping, additional, Lee, Ji‐Yuh, additional, Chen, Chi‐Yi, additional, Kao, Wei‐Yu, additional, Lin, Chih‐Lin, additional, Yang, Sheng‐Shun, additional, Shih, Yu‐Lueng, additional, Peng, Cheng‐Yuan, additional, Lee, Fu‐Jen, additional, Tsai, Ming‐Chang, additional, Huang, Shang‐Chin, additional, Su, Tung‐Hung, additional, Tseng, Tai‐Chung, additional, Liu, Chun‐Jen, additional, Chen, Pei‐Jer, additional, and Kao, Jia‐Horng, additional

Published
2024
Full Text
View/download PDF

25. The benefits of hepatitis C viral eradication: a real-world nationwide cohort study in Taiwan

Author

Chang, Chin-Wei, primary, Hsu, Wei-Fan, additional, Tseng, Kuo-Chih, additional, Chen, Chi-Yi, additional, Cheng, Pin-Nan, additional, Hung, Chao-Hung, additional, Lo, Ching-Chu, additional, Bair, Ming-Jong, additional, Chen, Chien-Hung, additional, Lee, Pei-Lun, additional, Lin, Chun-Yen, additional, Kuo, Hsing-Tao, additional, Chen, Chun-Ting, additional, Yang, Chi-Chieh, additional, Huang, Jee-Fu, additional, Tai, Chi-Ming, additional, Hu, Jui-Ting, additional, Lin, Chih-Lang, additional, Su, Wei-Wen, additional, Tsai, Wei-Lun, additional, Huang, Yi-Hsiang, additional, Cheng, Chien-Yu, additional, Lin, Chih-Lin, additional, Wang, Chia-Chi, additional, Yang, Sheng-Shun, additional, Mo, Lein-Ray, additional, Chen, Guei-Ying, additional, Chang, Chun-Chao, additional, Wang, Szu-Jen, additional, Huang, Chia-Sheng, additional, Hsieh, Tsai-Yuan, additional, Lin, Chih-Wen, additional, Lee, Tzong-Hsi, additional, Chong, Lee-Won, additional, Huang, Chien-Wei, additional, Chang, Shiuh-Nan, additional, Tsai, Ming-Chang, additional, Hsu, Shih-Jer, additional, Kao, Jia-Horng, additional, Liu, Chun-Jen, additional, Liu, Chen-Hua, additional, Lin, Han-Chieh, additional, Tsai, Pei-Chien, additional, Yeh, Ming-Lun, additional, Huang, Chung-Feng, additional, Dai, Chia-Yen, additional, Chuang, Wan-Long, additional, Yu, Ming-Lung, additional, and Peng, Cheng-Yuan, additional

Published
2024
Full Text
View/download PDF

26. Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)

Author

Yeh, Ming-Lun, Hung, Chao-Hung, Tseng, Kuo-Chih, Lai, Hsueh-Chou, Chen, Chi-Yi, Kuo, Hsing-Tao, Wang, Jing-Houng, Chen, Jyh-Jou, Lee, Pei-Lun, Chien, Rong-Nan, Yang, Chi-Chieh, Lo, Gin-Ho, Tai, Chi‐Ming, Lin, Chih-Wen, Kao, Jia-Horng, Liu, Chen-Hua, Yan, Sheng-Lei, Bair, Ming-Jong, Lin, Chun-Yen, Su, Wei-Wen, Chu, Cheng-Hsin, Chen, Chih-Jen, Tung, Shui-Yi, Lo, Ching-Chu, Cheng, Pin-Nan, Chiu, Yen-Cheng, Wang, Chia-Chi, Cheng, Jin-Shiung, Tsai, Wei-Lun, Lin, Han-Chieh, Huang, Yi-Hsiang, Huang, Chung-Feng, Huang, Jee-Fu, Dai, Chia-Yen, Chuang, Wan-Long, Tsai, Pei-Chien, Peng, Cheng-Yuan, Liu, Chun-Jen, and Yu, Ming-Lung

Published
2021
Full Text
View/download PDF

27. Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan

Author

Liu, Chen-Hua, Chen, Po-Yueh, Chen, Jyh-Jou, Lo, Ching-Chu, Su, Wei-Wen, Tseng, Kuo-Chih, Liu, Chun-Jen, Huang, Chia-Sheng, Huang, Ke-Jhang, Yang, Sheng-Shun, Peng, Cheng-Yuan, Tsai, Ming-Chang, Kao, Wei-Yu, Chang, Chi-Yang, Shih, Yu-Lueng, Fang, Yu-Jen, Chen, Chi-Yi, Lee, Pei-Lun, Huang, Jow-Jyh, Su, Pei-Yuan, Tseng, Chi-Wei, Hung, Chien-Ching, Chang, Chung-Hsin, Huang, Yi-Jie, Lai, Hsueh-Chou, Chang, Chun-Chao, Lee, Fu-Jen, Hsieh, Tsai‐Yuan, and Kao, Jia-Horng

Published
2021
Full Text
View/download PDF

28. Cutting-edge pharmacotherapy for hepatitis C virus infection: a comprehensive review.

Author

Liu, Chen-Hua, Chang, Yu-Ping, and Kao, Jia-Horng

Subjects
DRUG therapy, HEPATITIS C virus, INTERFERONS, SOFOSBUVIR, PHARMACOKINETICS
Abstract

Introduction: Pharmacotherapy against hepatitis C virus (HCV) infection has tremendously improved since the advent of interferon (IFN)-free direct-acting antivirals (DAAs). Additionally, fixed-dose pangenotypic DAAs, which are safe, potent, easy for use, and can cover a wide spectrum of patients, have been recommended by professional guidelines for DAA-naïve and DAA-experienced patients with HCV. Areas covered: We review the pharmacokinetics, pharmacodynamics, and potential drug–drug interactions (DDIs) of fixed-dose pangenotypic DAA regimens, including glecaprevir/pibrentasvir (GLE/PIB), sofosbuvir/velpatasvir (SOF/VEL), and sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX). Additionally, we summarize the efficacy and safety of these regimens in clinical trials as well as real-world studies for treating different populations. Lastly, we discuss unmet medical needs in managing HCV in the era of fixed-dose pangenotypic DAAs. Expert opinion: Protease inhibitors (PIs), including GLE and VOX, are prone to have more frequent DDIs, compared to the non-structural (NS) 5A and 5B inhibitors. These regimens are generally well tolerated and can be applied to different populations, except for the contraindicated use of PI-containing DAA regimens in decompensated cirrhosis. Using the first-line GLE/PIB and SOF/VEL can eradicate HCV in more than 95% of DAA-naïve patients across different populations. The viral cure usually exceeds 95% when using the rescue SOF/VEL/VOX regimen for prior DAA failures. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. Serum Mac‐2 binding protein glycosylation isomer dynamics in patients achieving sustained virologic response for hepatitis C virus.

Author

Chang, Yu‐Ping, Liu, Chen‐Hua, Huang, Chiuan‐Bo, Lee, Ji‐Yuh, Liu, Chun‐Jen, Su, Tung‐Hung, Huang, Shang‐Chin, Tseng, Tai‐Chung, Chen, Pei‐Jer, and Kao, Jia‐Horng

Subjects
*HEPATITIS C virus, *CARRIER proteins, *ISOMERS, *RECEIVER operating characteristic curves, *GLYCOSYLATION
Abstract

Background and Aim Methods Results Conclusions Understanding the dynamics of serum Mac‐2 binding protein glycosylation isomer (M2BPGi) remains pivotal for hepatitis C virus (HCV) patients' post‐sustained virologic response (SVR12) through direct‐acting antivirals (DAAs).We compared areas under receiver operating characteristic curves (AUROCs) of M2BPGi, FIB‐4, and APRI and assess M2BPGi cutoff levels in predicting fibrosis stages of ≥F3 and F4 utilizing transient elastography in 638 patients. Variations in M2BPGi levels from pretreatment to SVR12 and their association with pretreatment alanine transaminase (ALT) levels and fibrosis stage were investigated.The AUROCs of M2BPGi were comparable to FIB‐4 in predicting ≥F3 (0.914 vs 0.902, P = 0.48) and F4 (0.947 vs 0.915, P = 0.05) but were superior to APRI in predicting ≥F3 (0.914 vs 0.851, P = 0.001) and F4 (0.947 vs 0.857, P < 0.001). Using M2BPGi cutoff values of 2.83 and 3.98, fibrosis stages of ≥F3 and F4 were confirmed with a positive likelihood ratio ≥10. The median M2BPGi change was −0.55. Patients with ALT levels ≥5 times ULN or ≥F3 demonstrated more pronounced median decreases in M2BPGi level compared to those with ALT levels 2–5 times ULN and <2 times ULN (−0.97 vs −0.68 and −0.44; P < 0.001) or with < F3 (−1.52 vs −0.44; P < 0.001).Serum M2BPGi is a reliable marker for advanced hepatic fibrosis. Following viral clearance, there is a notable M2BPGi decrease, with the extent of reduction influenced by ALT levels and fibrosis stage. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy.

Author

Tsai, Pei-Chien, Huang, Chung-Feng, Yeh, Ming-Lun, Hsieh, Meng-Hsuan, Kuo, Hsing-Tao, Hung, Chao-Hung, Tseng, Kuo-Chih, Lai, Hsueh-Chou, Peng, Cheng-Yuan, Wang, Jing-Houng, Chen, Jyh-Jou, Lee, Pei-Lun, Chien, Rong-Nan, Yang, Chi-Chieh, Lo, Gin-Ho, Kao, Jia-Horng, Liu, Chun-Jen, Liu, Chen-Hua, Yan, Sheng-Lei, and Lin, Chun-Yen

Published
2024
Full Text
View/download PDF

32. Four weeks of off-treatment follow-up is sufficient to determine virologic responses at off-treatment week 12 in patients with hepatitis C virus infection receiving pangenotypic direct-acting antivirals

Author

Liu, Chen-Hua, primary, Chang, Yu-Ping, additional, Lee, Ji-Yuh, additional, Chen, Chi-Yi, additional, Kao, Wei-Yu, additional, Lin, Chih-Lin, additional, Yang, Sheng-Shun, additional, Shih, Yu-Lueng, additional, Peng, Cheng-Yuan, additional, Lee, Fu-Jen, additional, Tsai, Ming-Chang, additional, Huang, Shang-Chin, additional, Su, Tung-Hung, additional, Tseng, Tai-Chung, additional, Liu, Chun-Jen, additional, Chen, Pei-Jer, additional, and Kao, Jia-Horng, additional

Published
2024
Full Text
View/download PDF

34. Comparison of diagnostic performance among Abbott RealTime HCV Genotyping II, Abbott HCV Genotype plus RUO, and Roche Cobas HCV Genotyping assays for hepatitis C virus genotyping.

Author

Chang, Yu‐Ping, Huang, Chiuan‐Bo, Su, Tung‐Hung, Liu, Chun‐Jen, Tseng, Tai‐Chung, Huang, Shang‐Chin, Chen, Pei‐Jer, Kao, Jia‐Horng, and Liu, Chen‐Hua

Subjects
HEPATITIS C virus, GENOTYPES, NUCLEOTIDE sequencing, VIRAL load
Abstract

Comparison of diagnostic accuracy for commercial hepatitis C virus (HCV) genotyping (Abbott RealTime HCV Genotyping II, Roche Cobas Genotyping) and investigational Abbott HCV Genotype plus RUO assays designed to discriminate genotype (GT)‐1a, 1b or 6 in cases of ambiguous GT from the Abbott commercial assay remains limited. 743 HCV‐viremic samples were subjected to analysis using Abbott and Roche commercial as well as Abbott HCV Genotype plus RUO assays. Next‐generation sequencing (NGS) targeting core region was employed as the reference standard. Diagnostic accuracy was reported as the number of participants (percentages) along with 95% confidence intervals (CIs). Using NGS, 741 samples (99.7%) yielded valid genotyping results. The diagnostic accuracies were 97.6% (95% CI: 96.1%–98.5%) and 95.3% (95% CI: 93.4%–96.6%) using Abbott and Roche commercial assays (p = 0.0174). Abbott commercial assay accurately diagnosed HCV GT‐6a and 6w, whereas Roche commercial assay accurately diagnosed HCV GT‐6a. Both assays demonstrated low accuracies for HCV GT‐6b, 6e, 6g, and 6n. Abbott HCV Genotype plus RUO assay discriminated 13 of the 14 samples (92.9%; 95% CI: 64.2%–99.6%) that yielded ambiguous GT. Both assays were capable of diagnosing mixed HCV infections when the minor genotype comprised >8.4% of the viral load. The diagnostic performance of commercial HCV genotyping assays is commendable. Abbott assay demonstrated superior performance compared to Roche assay in diagnosing HCV GT‐6. Abbott HCV Genotype plus RUO assay aids in discriminating ambiguous GT. Both commercial assays are proficient in diagnosing mixed HCV infections at a cut‐off viral load of 8.4% in minor genotype. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

36. Metabolic Dysfunction-Associated Steatotic Liver Disease Facilitates Hepatitis B Surface Antigen Seroclearance and Seroconversion

Author

Huang, Shang-Chin, primary, Su, Tung-Hung, additional, Tseng, Tai-Chung, additional, Chen, Chi-Ling, additional, Hsu, Shih-Jer, additional, Liu, Chen-Hua, additional, Liao, Sih-Han, additional, Hong, Chun-Ming, additional, Lan, Ting-Yuan, additional, Yang, Hung-Chih, additional, Liu, Chun-Jen, additional, Chen, Pei-Jer, additional, and Kao, Jia-Horng, additional

Published
2023
Full Text
View/download PDF

39. Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium

Author

Huang, Chung-Feng, Iio, Etsuko, Jun, Dae Won, Ogawa, Eiichi, Toyoda, Hidenori, Hsu, Yao-Chun, Haga, Hiroaki, Iwane, Shinji, Enomoto, Masaru, Lee, Dong Hyun, Wong, Grace, Liu, Chen-Hua, Tada, Toshifumi, Chuang, Wan-Long, Cheung, Ramsey, Hayashi, Jun, Tseng, Cheng-Hao, Yasuda, Satoshi, Tran, Sally, Kam, Leslie, Henry, Linda, Jeong, Jae Yoon, Nomura, Hideyuki, Park, Seung Ha, Nakamuta, Makoto, Huang, Jee-Fu, Tai, Chi-Ming, Lo, Gin-Ho, Lee, Mei-Hsuan, Yang, Hwai-I, Kao, Jia-Horng, Tamori, Akihiro, Eguchi, Yuichiro, Ueno, Yoshiyuki, Furusyo, Norihiro, Tanaka, Yasuhito, Yu, Ming-Lung, and Nguyen, Mindie H.

Published
2019
Full Text
View/download PDF

40. Serial increase and high alpha‐fetoprotein levels predict the development of hepatocellular carcinoma in 6 months

Author

Su, Tung‐Hung, primary, Chang, Shan‐Han, additional, Chen, Chi‐Ling, additional, Liao, Sih‐Han, additional, Tseng, Tai‐Chung, additional, Hsu, Shih‐Jer, additional, Hong, Chun‐Ming, additional, Liu, Chen‐Hua, additional, Yang, Hung‐Chih, additional, Liu, Chun‐Jen, additional, Chen, Pei‐Jer, additional, and Kao, Jia‐Horng, additional

Published
2023
Full Text
View/download PDF

43. Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis

Author

Hsu, Wei-Fan, Chen, Chi-Yi, Tseng, Kuo-Chih, Lai, Hsueh-Chou, Kuo, Hsing-Tao, Hung, Chao-Hung, Tung, Shui-Yi, Wang, Jing-Houng, Chen, Jyh-Jou, Lee, Pei-Lun, Chien, Rong-Nan, Lin, Chun-Yen, Yang, Chi-Chieh, Lo, Gin-Ho, Tai, Chi-Ming, Lin, Chih-Wen, Kao, Jia-Horng, Liu, Chun-Jen, Liu, Chen-Hua, Yan, Sheng-Lei, Bair, Ming-Jong, Su, Wei-Wen, Chu, Cheng-Hsin, Chen, Chih-Jen, Lo, Ching-Chu, Cheng, Pin-Nan, Chiu, Yen-Cheng, Wang, Chia-Chi, Cheng, Jin-Shiung, Tsai, Wei-Lun, Lin, Han-Chieh, Huang, Yi-Hsiang, Tsai, Pei-Chien, Huang, Jee-Fu, Dai, Chia-Yen, Chuang, Wan-Long, Yu, Ming-Lung, and Peng, Cheng-Yuan

Published
2020
Full Text
View/download PDF

45. Long-term durability of sustained virologic response for hepatitis C virus infection in solid organ transplant recipients receiving direct-acting antivirals

Author

Liu, Chen-Hua, primary, Chen, Yih-Sharng, additional, Tsai, Meng-Kun, additional, Wang, Sheoi-Shen, additional, Lee, Chih-Yuan, additional, Tsao, Chuan-I, additional, Liu, Chun-Jen, additional, Su, Tung-Hung, additional, Tseng, Tai-Chung, additional, Huang, Shang-Chin, additional, Wu, Jo-Hsuan, additional, Chen, Pei-Jer, additional, and Kao, Jia-Horng, additional

Published
2023
Full Text
View/download PDF

46. Optimizing Survival Benefit by Surgical Resection by the Seven-Eleven Criteria in Barcelona Clinic Liver Cancer Stage A/B Hepatocellular Carcinoma beyond the Milan Criteria

Author

Huang, Chian-Tzu, Chu, Yu-Long, Su, Tung-Hung, Huang, Shang-Chin, Tseng, Tai-Chung, Hsu, Shih-Jer, Liao, Sih-Han, Hong, Chun-Ming, Liu, Chen-Hua, Yang, Hung-Chih, Liu, Chun-Jen, Chen, Pei-Jer, and Kao, Jia-Horng

Abstract

Introduction:Optimal treatment of hepatocellular carcinoma (HCC) beyond the Milan criteria is in debate. We aimed to identify candidates for surgical resection (SR) in Barcelona Clinic Liver Cancer (BCLC)-A/B HCC beyond the Milan criteria with survival benefit. Methods:Patients with BCLC-A/B HCC beyond the Milan criteria at the National Taiwan University Hospital during 2005 and 2019 were screened, and those who received transarterial chemoembolization (TACE) or SR were consecutively included. The tumor burden was classified by the seven-eleven criteria into low (≤7), intermediate (7–11), or high (>11). Multivariable Cox proportional hazard regression analysis was used for outcome prediction. Results:Overall, 474 patients who received SR (n= 247) and TACE (n= 227) were enrolled. Patients who underwent SR were significantly younger with better liver reserve. There were 76 (31%) and 129 (57%) deaths in the SR and TACE groups after a median follow-up of 3.9 and 2.1 years, respectively. The seven-eleven criteria could distinguish median overall survival (OS) among low (n= 149), intermediate (n= 203), and high (n= 122) tumor burden groups (7.7 vs. 6.9 vs. 2.8 years, respectively, p< 0.001). Patients receiving SR had a significantly higher median OS compared with TACE in those with intermediate (8.2 vs. 2.6 years, p< 0.001) and high (5.6 vs. 1.5 years, p= 0.001) tumor burden. After adjustment for age, sex, and liver reserve, SR was predictive for better OS in intermediate (adjusted hazard ratio [aHR]: 0.45, 95% confidence interval [CI]: 0.27–0.75) and high tumor burden groups (aHR: 0.54, 95% CI: 0.32–0.92). The survival benefit of SR especially confines to patients within 3 tumors. Conclusions:In patients with BCLC-A/B HCC beyond the Milan criteria with tumor burden beyond the up-to-7 criteria but within 3 tumors, SR has better OS than TACE and should be considered in resectable patients.

Published
2023
Full Text
View/download PDF

50. Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan

Author

Liu, Chen-Hua, primary, Peng, Cheng-Yuan, additional, Liu, Chun-Jen, additional, Chen, Chi-Yi, additional, Lo, Ching-Chu, additional, Tseng, Kuo-Chih, additional, Su, Pei-Yuan, additional, Kao, Wei-Yu, additional, Tsai, Ming-Chang, additional, Tung, Hung-Da, additional, Cheng, Hao-Tsai, additional, Lee, Fu-Jen, additional, Huang, Chia-Sheng, additional, Huang, Ke-Jhang, additional, Shih, Yu-Lueng, additional, Yang, Sheng-Shun, additional, Wu, Jo-Hsuan, additional, Lai, Hsueh-Chou, additional, Fang, Yu-Jen, additional, Chen, Po-Yueh, additional, Hwang, Jow-Jyh, additional, Tseng, Chi-Wei, additional, Su, Wei-Wen, additional, Chang, Chun-Chao, additional, Lee, Pei-Lun, additional, Chen, Jyh-Jou, additional, Chang, Chi-Yang, additional, Hsieh, Tsai‐Yuan, additional, Chang, Chung-Hsin, additional, Huang, Yi-Jie, additional, and Kao, Jia-Horng, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results